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and impaired glycolysis selectively in muscle. These meta-
bolic changes occurred before denervation and were associ-
ated with a concurrent enhancement of mechanistic target 
of rapamycin (mTOR) signaling, which induced peroxi-
some proliferator-activated receptor γ coactivator 1 alpha 
(PGC1α) expression. At later stages of disease, we detected 
mitochondrial membrane depolarization, enhanced tran-
scription factor EB (TFEB) expression and autophagy, and 
mTOR-induced protein synthesis. Several of these abnor-
malities were detected in the muscle of SBMA patients. 
Feeding knock-in mice a high-fat diet (HFD) restored 
mTOR activation, decreased the expression of PGC1α, 
TFEB, and genes involved in oxidative metabolism, 
reduced mitochondrial abnormalities, ameliorated mus-
cle pathology, and extended survival. These findings show 
early-onset and intrinsic metabolic alterations in SBMA 
muscle and link lipid/glucose metabolism to pathogenesis. 
Abstract Spinal and bulbar muscular atrophy (SBMA) is 
a neuromuscular disease caused by the expansion of a poly-
glutamine tract in the androgen receptor (AR). The mecha-
nism by which expansion of polyglutamine in AR causes 
muscle atrophy is unknown. Here, we investigated patho-
logical pathways underlying muscle atrophy in SBMA 
knock-in mice and patients. We show that glycolytic mus-
cles were more severely affected than oxidative muscles 
in SBMA knock-in mice. Muscle atrophy was associated 
with early-onset, progressive glycolytic-to-oxidative fiber-
type switch. Whole genome microarray and untargeted 
lipidomic analyses revealed enhanced lipid metabolism 
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Moreover, our results highlight an HFD regime as a prom-
ising approach to support SBMA patients.
Keywords Spinal and bulbar muscular atrophy · 
Androgen receptor · Skeletal muscle · mTOR · 
Rapamycin · PGC1α · High-fat diet
Introduction
Spinal and bulbar muscular atrophy (SBMA) is an X-linked 
motor neuron disease characterized by late-onset degen-
eration of lower motor neurons and skeletal muscle atro-
phy [41]. In addition, SBMA patients can develop non-
motor symptoms, such as sexual dysfunctions, diabetes, 
and severe urinary tract dysfunction, which are related to 
androgen insensitivity [75]. SBMA is caused by the expan-
sion of a polyglutamine tract in the gene encoding AR [43]. 
Polyglutamine expansions in specific genes are responsible 
for eight other neurodegenerative diseases, namely Hun-
tington’s disease (HD), dentatorubral–pallidoluysian atro-
phy, and spinocerebellar ataxia (SCA) type 1, 2, 3, 6, 7, and 
17 [67]. A unique feature of SBMA in the family of poly-
glutamine diseases is sex specificity: full manifestations 
are restricted to males. Sex specificity is due to the conver-
sion of polyglutamine-expanded AR to a toxic species that 
occurs upon binding to its natural ligand, testosterone. In 
its inactive state, AR localizes to cytosol. Binding of AR to 
testosterone results in nuclear translocation, DNA binding, 
interaction with transcriptional co-regulators, and regula-
tion (activation and repression) of expression of androgen-
responsive genes; these post-translational events have all 
been associated with pathogenesis [71]. Although several 
experimental and clinical strategies to modify disease have 
been tested to date [81], no effective therapy for SBMA has 
yet been developed.
Skeletal muscle (dys)function is emerging as a key com-
ponent of SBMA pathogenesis [84]. In addition to selective 
degeneration of motor neurons, SBMA patients develop 
progressive skeletal muscle weakness, fasciculations, and 
atrophy. SBMA patients show signs of muscle denervation, 
such as nerve sprouting, muscle fiber atrophy, and fiber-
type grouping, together with signs of muscle degeneration, 
such as splitting, presence of central nuclei, and degenera-
tion of fibers [96]. Neurogenic and myopathic processes 
have both been described in mouse models of SBMA [72, 
84]. Notably, knock-in SBMA mice show muscle pathol-
ogy that precedes spinal cord pathology [106]. Consistent 
with the idea that muscle plays a key role in pathogenesis, 
targeted overexpression of insulin-like growth factor 1 
(IGF-1) selectively in muscle ameliorated disease manifes-
tations in transgenic mice [70]. Unequivocal genetic evi-
dence for a primary role of muscle in SBMA pathogenesis 
was recently provided by the observation that expression of 
polyglutamine-expanded AR in all tissues except skeletal 
muscle was sufficient to prevent disease manifestations in 
transgenic mice [17]. Supporting these observations were 
concurrent studies demonstrating that knockdown of poly-
glutamine-expanded AR expression only in peripheral tis-
sues by antisense oligonucleotides was sufficient to attenu-
ate disease manifestations in SBMA knock-in mice [45]. 
However, how polyglutamine-expanded AR causes muscle 
atrophy remains to be clarified.
Alterations of metabolic pathways and of the nutrient 
and energy status at the organism and cell levels are emerg-
ing as key players in neurodegenerative diseases [11]. Skel-
etal muscle is a central nutrient- and stress-sensor and has 
a primary role in age-related neurodegenerative diseases 
[24]. Skeletal muscle regulates systemic aging by influenc-
ing metabolism and responses of the organism to dietary 
restriction and oxidative stress; as such, it affects both life 
span and the progression of age-related diseases [3, 25]. 
The homeostasis of skeletal muscle is maintained by a fine 
balance between anabolic and catabolic processes, which 
co-exist in a dynamic equilibrium to regulate the rate of 
protein synthesis and degradation (i.e., protein turnover) 
as well as muscle fiber size. Muscle hypertrophy is charac-
terized by an increase in muscle mass, which results from 
increased protein synthesis rate and muscle fiber size. On 
the other hand, muscle atrophy is characterized by reduced 
muscle mass, which results from reduced fiber size, 
increased protein degradation, and decreased force produc-
tion and fatigue resistance. This equilibrium is maintained 
by several signaling pathways, including the evolutionarily 
conserved IGF-1/Akt pathway [91]. Based on the central 
role of skeletal muscle in energy metabolism and the fact 
that muscle is an easier therapeutic target compared to the 
nervous system for neurodegenerative diseases, here we 
investigated pathological processes occurring in SBMA 
muscles.
Materials and methods
Animals and treatments
Animal care and experimental procedures were conducted 
in accordance with the Italian Institute of Technology 
and the University of Trento ethics committees and were 
approved by the Italian Ministry of Health. Generation 
and genotyping of knock-in AR21Q and AR113Q mice 
were previously described [106]. Mice were randomized 
and fed a standard diet (Mucedola 4RF21), purified nor-
mal chow diet (NCD, D12450B Research Diet), and 
high-fat diet (HFD, D12451 Research Diet) as indicated. 
The operator was blind for genotype and treatment. For 
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rotarod analysis (Ugo Basile), mice received a weekly ses-
sion, which included one trial followed by two test trials 
at 21 rpm speed for a maximum period of 600 s and the 
average of recordings was used. For rapamycin treatment, 
154-day-old mice were injected intraperitoneally with rapa-
mycin (4.0 mg/kg, Gold Biotechnology). For analysis of 
the rate of protein synthesis, animals were starved 30 min, 
injected with puromycin (0.040 μmol/g puromycin dis-
solved in 100 μl PBS), and sacrificed 30 min after injec-
tion. In vivo and ex vivo muscle force was measured as pre-
viously described [8].
Human samples
Anonymized control and patient biopsy sample collection 
was approved by the ethics committee of the University 
of Padova (Italy). Written informed consent was obtained 
from each patient. All patients who underwent muscle 
biopsy were clinically affected and showed weakness and/
or fasciculation and/or muscle atrophy. Myopathic changes 
together with neurogenic atrophy were observed in muscle 
biopsies.
Histological analysis
Muscles collected immediately after euthanasia were 
flash-frozen in isopentane precooled in liquid nitrogen and 
embedded in optimal cutting temperature (OCT) compound 
(Tissue Tek, Sakura), and cross sections (10 µm thick) were 
cut with a cryostat (CM1850 UV, Leica Microsystems). 
Cryosections were processed for hematoxylin and eosin 
(H/E) and nicotinamide adenine dinucleotide (NADH) 
staining, as previously described [70]. For immunofluo-
rescence analysis, muscle cryosections were incubated 
with M.O.M. IgG blocking solution (Vector), washed with 
phosphate-buffered saline (PBS) and incubated with a 
solution of PBS containing 0.5 % bovine serum albumin 
(BSA). Full list of antibodies used is provided in the Sup-
plementary Information. Sections were mounted with aque-
ous mounting medium (Fluorescence Mounting Medium, 
Dako). Images were taken using an upright epifluores-
cence microscope (Zeiss Axio Imager M2) equipped with 
an X-Cite 120Q fluorescence light source and a Zeiss Mrm 
Color Camera. Multichannel images and mosaics were 
taken using Zeiss Axio Vision Software (V.4.8.2 SP3).
Biochemical analysis
Muscles were mechanically pulverized and homogenized 
in lysis buffer [20 mM HEPES, 5 mM EGTA, 2 % sodium 
dodecyl sulfate (SDS)] and processed by SDS–polyacryla-
mide gels (SDS-PAGE) as previously described [70]. Full 
list of antibodies used is provided in the Supplementary 
Information. Signal intensities were quantified by Image-
Quant LAS 4000 mini (GE Healthcare BioSciences). Lac-
tate dehydrogenase (LDH) and citrate synthase activity 
was measured as previously described [42, 99]. For pro-
teasome activity assay, muscles were lysed using ice-cold 
lysis buffer [50 mM HEPES, 5 mM EDTA, 150 mM NaCl, 
2 mM ATP, 1 % Triton X-100], sonicated and centri-
fuged. Protein extracts were incubated in 25 mM HEPES, 
0.5 mM EDTA, 0.05 % NP40, 0.001 % SDS, and 0.5 mM 
N-Succinyl-Leu-Leu-Val-Tyr-7-Amido-4-Methylcoumarin 
(Sigma). The absorption was recorded at 460 nm by excita-
tion at 355 nm (Victor3-V luminometer, PerkinElmer).
High‑resolution LC–MS/MS analysis for lipidomic 
profiling, real‑time PCR, and microarray hybridization 
and data acquisition
Untargeted metabolomics experiments were performed 
as previously described [2]. For real-time analysis, total 
RNA was extracted with Trizol (Invitrogen), purified using 
RNeasy MinElute Cleanup Kit (QIAGEN), and reverse 
transcribed into cDNA using the iScript Reverse Transcrip-
tion Supermix (Bio-Rad). Gene expression was measured 
by quantitative real-time PCR using 7900 HT Fast Real-
Time PCR System (Applied Biosystems). The list of prim-
ers is provided in Supplementary Table 1. For microarray 
analysis, total RNA was purified using RNeasy MinElute 
Cleanup Kit (QIAGEN). High-quality RNA was used 
for labeling and array hybridization (Agilent Mouse GE 
4X44 K slides). Slides were scanned on the Agilent DNA 
Microarray Scanner (G2505C) using the AgilentHD_
GX_1Color Profile (scan area: 61 × 21.6 mm; scan reso-
lution: 5 μm, dye channel set to 100 % Green PMT) of 
Agilent ScanControl software 8.1.3. Images were analyzed 
with Feature Extraction Software 10.7.3.1 (Agilent Tech-
nologies) using default parameters (protocol GE1_107_
Sep09). Expression data were analyzed using the limma 
package from R and false discovery rate (FDR) control 
for statistical assessment of the microarray data (corrected 
P < 0.05 were considered significant). Gene set enrichment 
analysis (GSEA) was performed to identify sets of related 
genes altered in each experimental group (http://www.
broad.mit.edu/gsea). Heat maps were generated using MeV 
TM4 software V 4.9 (http://www.tm4.org). Microarray data 
are available at the Gene Expression Omnibus database 
under accession number GSE68441.
Mitochondrial membrane potential and complex 
activity analyses
Mitochondrial membrane potential was measured in 
isolated fibers from flexor digitorum brevis muscles. 
Mitochondrial membrane potential was measured by 
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epifluorescence microscopy based on the accumulation of 
tetramethyl rhodamine methyl ester (TMRM) fluorescence, 
as previously described [82]. For mitochondrial complex 
activity, total muscle lysates were extracted and the enzy-
matic activities of the respiratory chain complexes I–IV 
were assayed as previously described [99].
Statistical analysis
All data are presented as mean ± standard error of the 
mean (SEM). Statistical differences of continuous data 
from two experimental groups were calculated using two-
sample t tests. Comparisons of data from more than two 
groups were performed using a one-way ANOVA followed 
by a Fisher’s least significant difference post hoc test. Sta-
tistical comparisons of lifespan curves were performed 
using the log-rank and Gehan–Breslow–Wilcoxon tests. 
Statistical significance threshold was set at P < 0.05, unless 
otherwise indicated.
Results
Shift towards oxidative metabolism in glycolytic SBMA 
muscles
To elucidate the pathological processes underlying mus-
cle atrophy in SBMA, we used SBMA knock-in mice that 
express AR with a pathogenic polyglutamine tract of 113 
glutamine residues (AR113Q) and, as controls, AR21Q and 
wild-type littermates [72]. No signs of muscle atrophy were 
detected in AR21Q mice (Supplementary Fig. 1a), as previ-
ously described [107]. To determine whether expression of 
polyglutamine-expanded AR differentially affects muscles 
composed primarily of either type I slow-oxidative fibers 
(e.g., soleus) or type II fast-glycolytic fibers [e.g., quadri-
ceps, gastrocnemius, tibialis anterior (TA)], we assessed 
the wet weight of these muscles as a function of disease 
progression. The mass of quadriceps, gastrocnemius, and 
TA was reduced by 13–35 % beginning at 60 or 90 days 
of age, whereas the mass of soleus did not change over 
the course of disease in AR113Q mice compared to age-
matched control mice (Fig. 1a; Supplementary Fig. 1b). 
By H/E analysis, the mean myofiber cross-sectional area 
(CSA) of quadriceps, gastrocnemius, and TA muscles was 
decreased by 10–30 % in 90- and 180-day-old AR113Q 
mice, whereas that of soleus was increased (Supplemen-
tary Fig. 2a–c). Tetanic force production was decreased by 
27 % in the gastrocnemius, but not soleus (Supplementary 
Fig. 1c, d), indicating that structural alterations are associ-
ated with functional deficits. Notably, the degree of atrophy 
correlated with the levels of expression of AR, suggesting 
a dose-dependent effect of polyglutamine-expanded AR 
in muscle (Fig. 1b). These results indicate that expression 
of AR113Q preferentially affects glycolytic muscles com-
pared to oxidative muscles.
Analysis of muscle biopsies has revealed that the num-
ber of type I oxidative fibers is increased in the glycolytic 
muscles of SBMA patients, suggesting metabolic altera-
tions [38]. By NADH staining, we observed a progressive 
shift from fast-glycolytic towards slow-oxidative fiber sub-
type in the quadriceps and gastrocnemius of AR113Q mice, 
which was detected as early as 40 days of age (Fig. 1c; 
Supplementary Fig. 3a, b). Staining of type IIa (fast-oxi-
dative) and IIb (fast-glycolytic) fibers confirmed that the 
number of type IIb fibers was decreased, whereas that of 
type IIa was increased in the quadriceps of AR113Q mice. 
Notably, the mean CSA of oxidative fibers was decreased 
by 10 % in 40-day-old AR113Q mice and progressed to 
16 % in 180-day-old mice, whereas that of glycolytic fibers 
was decreased by 10 % at 40 days of age and progressed 
to 40 % at 180 days of age in the quadriceps and gastroc-
nemius (Fig. 1d; Supplementary Fig. 4a, b). These results 
indicate an early-onset glycolytic-to-oxidative fiber-type 
switch with atrophy of glycolytic fibers exceeding that of 
oxidative fibers in the muscle of SBMA knock-in mice.
Glycolysis is impaired in SBMA muscles
Given that oxidative and glycolytic fibers primarily use 
oxidative phosphorylation and glycolysis to generate 
ATP, respectively, we hypothesized that the lipid profile 
of AR113Q mice was altered. Using untargeted high-res-
olution LC–MS/MS lipidomic and unsupervised princi-
pal component analyses, we identified major lipid altera-
tions in muscle, but not serum, with 45 lipids significantly 
(P ≤ 0.001) enriched (fold change >1.5) and 22 lipids 
decreased (fold change <0.5) in AR113Q mice (Fig. 2a; 
Supplementary Fig. 5a; Supplementary Table 2). Lysophos-
phatidylcholines, lysophosphatidylethanolamines, cera-
mides, diglycerides, and polyunsaturated fatty acids were 
increased, whereas species enriched in polyunsaturated 
lipids and phosphatidylglycerol were decreased, suggest-
ing increased lipid synthesis and turnover. To investigate 
the molecular pathways underlying the metabolic altera-
tions detected in glycolytic SBMA muscles, we performed 
whole genome microarray analysis on quadriceps mus-
cle. We identified 550 upregulated (fold change ≥1.5) 
genes and 286 downregulated (fold change ≤0.6) genes 
in the quadriceps of 180-day-old AR113Q mice com-
pared to age-matched control mice (P < 0.05, false dis-
covery rate <0.05) (Supplementary Fig. 5b; Supplemen-
tary Table 3). Consistent with the glycolytic-to-oxidative 
metabolic shift described above, the transcript levels of 
markers of oxidative fibers, such as troponin I1 (Tnni1), 
troponin C1 (Tnnc1), troponin T1 (Tnnt1), ankyrin repeat 
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Fig. 1  Glycolytic-to-oxidative fiber-type switch in SBMA glycolytic 
muscles. a Muscle weight (MW) normalized to body weight (BW) 
of the indicated skeletal muscles of AR113Q and control (CTR, wild 
type) mice analyzed as a function of disease progression. Graphs 
show mean ± sem, n = 3–10 mice. b Western blotting analysis of AR 
expression levels in quadriceps (quadri), gastrocnemius (gastro), tibi-
alis anterior (TA), and soleus muscles of 90-day-old AR113Q mice. 
AR was detected with specific antibody, and actin was used as load-
ing control. Graph shows mean ± sem, n = 3. c Left NADH stain-
ing of quadriceps from AR113Q and CTR (wild type) mice. Graphs 
show mean ± sem, n = 3–8 mice. Right NADH staining (top panel) 
and immunofluorescence of type IIa (green) and IIb (red) myosin 
heavy chain-positive fibers (bottom panel) in the quadriceps muscle 
of 180-day-old AR113Q and CTR mice. Shown are representative 
images from n = 3 mice. d Analysis of the mean oxidative and gly-
colytic myofiber CSA in the quadriceps of AR113Q and CTR (wild 
type) mice. Graphs show mean ± sem, n = 3 mice
Fig. 2  Lipid metabolism is enhanced and glycolysis is impaired in 
the glycolytic muscles of SBMA knock-in mice. a Score plot from 
principal component analysis of high-resolution LC–MS/MS shotgun 
lipidomic analysis in the quadriceps muscle of 180-day-old AR113Q 
and CTR (wild type) mice (n = 6–7 mice). b GSEA analysis of path-
ways enriched in genes differentially expressed in AR113Q mice 
compared to age-matched CTR (wild type) mice. NES normalized 
enrichment score. c, d Real-time PCR analysis of the transcript lev-
els of lipid and glycolytic genes normalized to beta-glucuronidase in 
the quadriceps muscle of 180-day-old AR113Q and CTR (wild type) 
mice. Graph shows mean ± sem, n = 5 mice. e Western blotting anal-
ysis of glycolytic protein expression levels in the muscle of 180-day-
old AR113Q and CTR (wild type) mice. Graphs show mean ± sem, 
n = 5 mice. Calnexin (CNX) and actin were used as loading control. f 
Enzymatic activity of lactate dehydrogenase (LDH) in the quadriceps 
of 180-day-old AR113Q and CTR (wild type) mice. Graph shows 
mean ± sem, n = 3–5 mice
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domain 2 (Ankrd2), myoglobin (Mb), myosin heavy chain 
7b (Myh7b), were all upregulated, whereas those of gly-
colytic fibers were either decreased, such as 5′-AMP-
activated protein kinase subunit gamma-3 (Prkag3), or 
remained unchanged, such as troponin I2 (TnnI2), myosin 
heavy chain 4 (Myh4), and parvalbumin (Pvalb) (Supple-
mentary Table 4). Gene set enrichment analysis (GSEA) 
revealed that the top pathways enriched in genes differen-
tially expressed in AR113Q and control mice were meta-
bolic pathways (Fig. 2b; Supplementary Table 5). The 
gene set “starch/sucrose metabolism”, which includes gly-
colytic genes, was downregulated, whereas “peroxisome 
proliferator-activated receptor alpha (PPARα) signaling”, 
“glycerolipid and fatty acid metabolism”, and “tricarbox-
ylic acid (TCA) cycle” were upregulated. Similar changes 
in metabolic pathways were also detected in transgenic 
mice overexpressing AR97Q (Supplementary Table 5) [57]. 
By real-time PCR analysis, we validated the upregulation 
of genes involved in lipid metabolism, such as fatty acid 
synthase (Fasn), which catalyzes the synthesis of palmi-
tate from malonyl-coenzyme A and acetyl-coenzyme A in 
a process that requires NADPH, aldehyde dehydrogenase 9 
subfamily A1 (Aldh9a1), which detoxifies from accumula-
tion of aldehydes generated by lipid peroxidation through 
NAD(P)+-dependent oxidation to carboxylic acids, dia-
cylglycerol O-acyltransferase 2 (Dgat2), which catalyzes 
the synthesis of triglycerides from diacylglycerol and acyl-
coenzyme A, the mitochondrial protein cell death-inducing 
DNA fragmentation factor alpha subunit-like effector A 
(Cidea), which plays a role in thermogenesis and lipolysis, 
the sarcoplasmic reticulum SERCA Ca(2+)-ATPase A2 
(Atp2a2), and Ppara, which is involved in the regulation 
of muscle metabolism (Fig. 2c). Importantly, the expres-
sion of these genes was not altered in soleus (Supplemen-
tary Fig. 6a). The expression and activity of key enzymes 
in the glycolytic pathway, such as hexokinase II (Hk II), 
phosphofructokinase 1 (Pfkm), 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 3 (Pfkb3), glyceraldehyde 
3-phosphate dehydrogenase (Gapdh), phosphoglycerate 
kinase 1 (Pgk1), and lactate dehydrogenase (LDH), were 
downregulated in the quadriceps muscle of AR113Q mice, 
whereas the activity of citrate synthase (CS) was increased 
(Fig. 2d–f; Supplementary Fig. 5c, d). Alterations in glyco-
lytic gene expression preceded those in lipid gene expres-
sion, as they were detected as early as 90 days of age in 
the quadriceps of AR113Q mice (Supplementary Fig. 7a, 
b). In soleus muscle, the transcript levels of Gapdh, and 
not the other glycolytic genes, were decreased by 40 % at 
180 days of age (Supplementary Fig. 6b). Our microarray 
analysis also revealed that the transcript levels of SLC2A3, 
which encodes the glucose transporter 3 (GLUT3), were 
decreased by 60 %, suggesting altered glucose uptake, 
whereas those of SLC2A5, which encodes the solute carrier 
family 2 (facilitated glucose/fructose transporter), mem-
ber 5 (GLUT5), was upregulated by 4.7-fold in the muscle 
of AR113Q mice, suggesting compensatory mechanisms 
for carbohydrate uptake (Supplementary Table 2). Fasting 
serum glucose and insulin levels were similar in AR113Q 
and control mice (Supplementary Fig. 8a), and intraperi-
toneal glucose and insulin tolerance tests showed normal 
glucose clearance and insulin sensitivity in AR113Q mice 
(Supplementary Fig. 8b, c). Moreover, no overt altera-
tions in glycogen storage were detected in the quadriceps 
of 180-day-old AR113Q mice and SBMA patients (Sup-
plementary Fig. 9). Taken together, these results indicate 
that glycolytic muscles in SBMA knock-in mice show 
enhanced lipid metabolism and gene expression programs, 
as well as impaired glycolysis.
Unbalanced protein synthesis and degradation 
in glycolytic SBMA muscles
Muscle homeostasis is maintained by a fine balance 
between protein synthesis and degradation, two processes 
that simultaneously occur in muscle [100]. We hypoth-
esized that the metabolic changes detected in SBMA mus-
cle alter protein turnover. To assess the rate of new protein 
synthesis, we used in vivo surface sensing of translation 
(SUnSET) [92]. We intraperitoneally injected AR113Q and 
control mice with the antibiotic puromycin, and we ana-
lyzed the rate of new protein synthesis by Western blotting 
using an anti-puromycin antibody. The rate of new protein 
synthesis was increased by 35 and 73 % in the quadriceps 
muscle of 90- and 270-day-old AR113Q mice compared 
to age-matched control mice (Fig. 3a; Supplementary 
Fig. 10a); this increase was overt even upon 4 h of fast-
ing (Supplementary Fig. 10b). We assessed protein degra-
dation by analyzing ubiquitination of total protein lysates 
from quadriceps muscle of AR113Q and control mice. 
The amount of ubiquitinated proteins was increased by 
1.33- and 1.84-fold in the quadriceps of 90- and 270-day-
old AR113Q mice compared to control mice, respectively 
(Fig. 3b; Supplementary Fig. 10c). We observed increases 
in the expression of the E3 ubiquitin ligases, specific of 
muscle atrophy and regulated by transcription (Smart) and 
muscle ubiquitin ligase of the SCF complex in atrophy-1 
(Musa1) (Fig. 3c) [56, 88], as well as increased proteasome 
activity starting at 90 days of age in the quadriceps muscle 
of AR113Q mice, further indicating enhanced protein deg-
radation in the muscle of SBMA mice (Fig. 3d; Supplemen-
tary Fig. 10d). Notably, the net amount of protein content 
in the quadriceps and gastrocnemius muscles of AR113Q 
mice was reduced at 90 and 270 days of age (Fig. 3e; Sup-
plementary Fig. 10e). These alterations were not detected 
in soleus (Supplementary Fig. 11a, b). These results show 
that protein turnover (protein synthesis and breakdown) is 
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Fig. 3  Protein turnover and mTOR signaling are enhanced in SBMA 
glycolytic muscles. a Western blotting analysis of the rate of new 
protein synthesis in the quadriceps of 90-day-old AR113Q and CTR 
(wild type) mice intraperitoneally injected with the aminoacyl-tRNA 
analog puromycin. Puromycin incorporation was detected with anti-
puromycin (anti-pur) antibody, and Red Ponceau (Red P) was used 
as loading control. Graph shows mean ± sem, n = 3–5 mice. b West-
ern blotting analysis of protein ubiquitination in the quadriceps of 
90-day-old AR113Q and CTR (wild type) mice. Ubiquitinated pro-
teins were detected with anti-ubiquitin (anti-Ub) antibody. Graph 
shows mean ± sem, n = 4–6 mice. c Real-time PCR analysis of the 
indicated E3 ubiquitin ligase transcript levels normalized to actin in 
the quadriceps of AR113Q and CTR (wild type) mice. Graphs show 
mean ± sem, n = 4–6 mice. d Proteasome activity measured in the 
quadriceps of 90-day-old AR113Q and CTR (wild type) mice. Graph 
shows mean ± sem, n = 4 mice. e Total protein content in quadriceps 
(quadri) and gastrocnemius (gastro) muscles of 90-day-old AR113Q 
and CTR (wild type) mice. Graph shows mean ± sem, n = 4 mice. 
f Western blotting analysis of S6K1 and 4EBP1 phosphorylation 
and expression levels in the quadriceps of 90-day-old AR113Q and 
CTR (AR21Q) male mice. Graphs show mean ± sem, n = 3 mice. g 
Western blotting analysis of phosphorylated and total S6 levels in the 
quadriceps of AR113Q and CTR (wild type) mice treated with vehi-
cle (Veh) or rapamycin (Rapa). Graph shows mean ± sem, n = 6–8 
mice. Calnexin (CNX) was used as loading control. h Western blot-
ting analysis of the rate of new protein synthesis in the quadriceps 
of AR113Q and CTR (wild type) mice treated as in g. Graph shows 
mean ± sem, n = 6–7 mice
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increased in SBMA glycolytic, but not oxidative muscles, 
and that the increased rate of protein degradation is not 
compensated by the increased rate of protein synthesis.
Enhanced mTOR signaling is responsible for the 
increased rate of protein synthesis in SBMA glycolytic 
muscles
A key regulator of protein turnover in muscle is mTOR, 
a sensor of cellular metabolism and a regulator of gly-
colysis and lipid biosynthesis [30]. mTOR stimulates pro-
tein synthesis through phosphorylation of the eukaryotic 
translation initiation factor 4E binding protein 1 (4EBP1) 
and S6 kinase 1 (S6K1), which in turn phosphorylates the 
ribosomal protein S6. mTOR signaling was increased in 
the quadriceps, but not spinal cord, of 90- and 270-day-
old AR113Q male, and not female, mice (Fig. 3f; Supple-
mentary Fig. 12a). S6K1 phosphorylation was increased 
also in gastrocnemius and TA, which show atrophy, but 
not soleus, which is spared in this mouse model of SBMA 
(Supplementary Fig. 12b); the increase in mTOR signaling 
preceded atrophy, as it was detected as early as 40 days of 
age (Supplementary Fig. 12c). Enhanced mTOR signaling 
was not associated with increased expression of AR in male 
AR113Q mice compared to control mice (Supplementary 
Fig. 12a). Importantly, we did not detect alterations in the 
phosphorylation levels of Akt and its downstream effectors 
glycogen synthase kinase 3β (GSK3β) and forkhead box O 
transcription factors (FOXOs), suggesting that mTOR acti-
vation is independent of Akt. To assess whether enhanced 
mTOR signaling is responsible for the increased rate of 
new protein synthesis in SBMA muscle, we administered 
rapamycin (4 mg/kg/day) to AR113Q and control mice 
via intraperitoneal injections every day for 20 days. Rapa-
mycin treatment reduced S6 phosphorylation (Fig. 3g) 
and decreased the rate of new protein synthesis by 28 and 
32 % in control and AR113Q mice, respectively (Fig. 3h). 
Importantly, rapamycin decreased Akt phosphorylation in 
muscle, the body weight of AR113Q mice starting from 
16 days of treatment, without altering food intake, and 
testis size in both AR113Q and control mice (Supplemen-
tary Fig. 13a–d). Rapamycin did not modify skeletal mus-
cle mass (Supplementary Fig. 13e). Taken together, these 
results indicate that mTOR signaling is enhanced prior to 
atrophy, and it increases the rate of new protein synthesis in 
SBMA glycolytic muscles.
Metabolic alterations in muscle precede denervation, 
mitochondrial depolarization and autophagy induction, 
and correlate with PGC1α expression
Denervation may cause metabolic alterations in muscle 
associated with atrophy and loss of fast-glycolytic fibers 
[64]. Therefore, we investigated whether the metabolic 
changes detected in quadriceps result from denervation in 
SBMA knock-in mice (Fig. 4a). The transcript levels of two 
denervation markers, acetylcholine receptor subunit gamma 
(Chrng) and muscle-specific kinase (Musk), were upregu-
lated by 90 days of age, but not at 40 days of age, when 
the metabolic changes were started to be detected. More-
over, these denervation markers were not upregulated in 
the soleus of 180-day-old AR113Q mice (Supplementary 
Fig. 14a). These results indicate that the metabolic altera-
tions that occur in SBMA glycolytic muscles precede den-
ervation and are not initiated, rather maybe contributed at 
later stages of disease, by pathogenic processes occurring 
in motor neurons.
mTOR controls mitochondrial gene expression through 
modulation of PGC1α (Ppargc1a) function [20]. PGC1α 
is a master regulator of muscle metabolism, and when 
overexpressed it shifts muscle metabolism towards oxida-
tive phosphorylation [47]. PGC1α expression correlated 
with disease progression in the quadriceps, but not soleus 
of AR113Q mice (Fig. 4b; Supplementary Fig. 14b). In 
quadriceps, PGC1α induction showed a trend for signifi-
cance (P = 0.08) at 40 days of age, suggesting that its dys-
regulation occurs very early in disease pathogenesis, with 
dysregulation increasing with disease progression. Impor-
tantly, rapamycin treatment decreased PGC1α transcript 
levels, indicating that in SBMA muscle PGC1α expres-
sion is regulated by mTOR (Fig. 4c). PGC1α promotes 
mitochondrial biogenesis [104]. Markers of mitochon-
dria fission and fusion, such as dynamin-related protein 
1 (Dnm1 l, Drp1) and opticatrophy gene 1 (Opa1), were 
upregulated in the quadriceps, but not soleus of AR113Q 
mice (Fig. 4b; Supplementary Fig. 14b). Moreover, the 
activity of mitochondrial complexes was increased in 
the quadriceps of AR113Q mice (Fig. 4d; Supplemen-
tary Fig. 15a). Mitochondrial abnormalities have been 
reported in SBMA [79]. We measured mitochondrial 
membrane potential in myofibers isolated from the fast-
glycolytic flexor digitorum brevis muscle upon treatment 
with the F1F0-ATPase blocker, oligomycin (Fig. 4e; Sup-
plementary Fig. 15b). We found that the number of fibers 
with mitochondria depolarized by oligomycin was signifi-
cantly (P < 0.05) increased by 40 % in 90- and 180-day-
old AR113Q mice. These data indicate that despite the 
increased beta oxidative metabolism, mitochondria are 
dysfunctional in SBMA muscle and are a potential source 
of oxidative stress.
Mitochondrial depolarization and accumulation of reac-
tive oxygen species represent a signal for autophagy acti-
vation [90]. The autophagy markers microtubule-associated 
protein 1A/1B-light chain 3 (LC3) and sequestosome 1 
(Sqstm1, p62) are upregulated in the muscle of AR113Q 
mice, indicating enhanced autophagy [16, 83]. The 
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transcript levels of these autophagy markers were increased 
in the quadriceps, but not soleus, of 180-day-old AR113Q 
mice (Fig. 4f; Supplementary Fig. 14c). Upregulation of 
these autophagy markers in quadriceps was preceded by 
transcriptional induction of TfEB, the master regulator of 
autophagy gene expression [87]. To monitor autophagy 
flux, we measured the soluble mature form of LC3, namely 
LC3I, the membrane-bound form, LC3II, which accumu-
lates upon autophagosome formation, and p62, which 
accumulates upon inhibition of autophagy flux (Fig. 4g; 
Supplementary Fig. 16a–c). Both LC3I and II increased at 
late stages of disease (180 and 270 days of age), and the 
ratio LC3II/LC3I did not change over the progression of 
disease, whereas p62 significantly accumulated in 270-day-
old mice, suggesting defects in autophagy flux at very 
late stages of disease. These data indicate that metabolic 
changes in SBMA muscle precede TFEB upregulation and 
autophagy induction.
Fig. 4  PGC1α expression is induced by mTOR and precedes den-
ervation and autophagy activation in SBMA muscle. a–c Real-time 
PCR analysis of the indicated gene transcript levels normalized to 
actin in the muscle of AR113Q and CTR (wild type) mice. Graphs 
show mean ± sem, n = 4–6 mice. Veh vehicle, Rapa rapamycin. d 
Mitochondrial complex (C) I, II, III, and IV activity measured in the 
quadriceps of 180-day-old AR113Q and CTR (wild type) mice fed a 
normal chow diet (NCD) and a high-fat diet (HFD) and normalized 
to mitochondrial protein content. Graph shows mean ± sem, n = 4 
mice. NCP non-collagen proteins. e Mitochondrial membrane depo-
larization measured in fibers isolated from flexor digitorum brevis 
of 180-day-old mice fed either an NCD or an HFD. Graph shows 
mean ± sem, n = 3–4 mice, 10 fibers. Olm oligomycin, FCCP pro-
tonophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone 
TMRM, tetramethyl rhodamine methyl ester. f Real-time PCR 
analysis of the indicated gene transcript levels normalized to actin 
in the muscle of 180-day-old AR113Q and CTR (wild type) mice. 
Graphs show mean ± sem, n = 4–6 mice. g Western blotting analy-
sis of LC3I and II and p62 in the quadriceps muscle of 180-day-old 
AR113Q and CTR (wild type) mice fed an NCD and an HFD. Graphs 
show mean ± sem, n = 4–6 mice
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An HFD ameliorates the phenotype of knock‑in SBMA 
mice
mTOR and PGC1α can be inhibited by feeding mice an 
HFD [6, 97]. Therefore, we administered AR113Q and 
control mice either an HFD or the NCD (Supplementary 
Fig. 17). Treatment was started at 40 days of age. The HFD 
reduced the changes in gene expression detected in SBMA 
muscle (Supplementary Fig. 18a, Tables 3–5), including 
Ppargc1a (PGC1α), genes involved in lipid metabolism, 
and TfEB (Fig. 5a), it reduced mitochondrial membrane 
depolarization by 50 % without altering the activity of mito-
chondrial complexes (Fig. 4d, e), it increased LC3 lipidation 
(Fig. 4g), and it restored the activation of mTOR signaling 
to normal levels (Fig. 5b). The HFD did not affect the lev-
els of expression of polyglutamine-expanded AR (Supple-
mentary Fig. 18b). The HFD increased the wet weight of 
quadriceps (Fig. 5c) but not gastrocnemius (Supplementary 
Fig. 19a), and reduced the number of slow-oxidative fib-
ers by 20 % in both quadriceps and gastrocnemius mus-
cles of SBMA mice (Fig. 5d; Supplementary Fig. 19b, 
c), it increased the mean CSA of oxidative fibers in the 
Fig. 5  An HFD ameliorates the phenotype of SBMA knock-in mice. 
a Real-time PCR analysis of the transcript levels of selected genes in 
the muscle of 180-day-old AR113Q mice fed as indicated and nor-
malized to beta-glucuronidase and actin. Graphs show mean ± sem, 
n = 5 mice. b Western blotting analysis of phosphorylated and total 
S6 in the quadriceps of 180-day-old AR113Q and CTR (wild type) 
mice fed either NCD or HFD. Calnexin (CNX) was used as load-
ing control. Graph shows mean ± sem, n = 4–8 mice. c Analysis of 
quadriceps wet weight in AR113Q and CTR (wild type) mice fed as 
indicated. Graph shows mean ± sem, n = 4–8 mice. d NADH stain-
ing analysis in the quadriceps of 180-day-old AR113Q mice fed 
either NCD or HFD. Graph shows mean ± sem, n = 3–4 mice. e 
Analysis of epididymal fat weight in 180-day-old AR113Q and CTR 
(wild type) mice fed as indicated. Graph shows mean ± sem, n = 3–9 
mice. f Body weight analysis of AR113Q and CTR (wild type) fed 
either NCD or HFD. Graph shows mean ± sem, n = 18–21 mice. 
g Kaplan–Meier analysis of survival (n = 32 CTR-NCD, 29 CTR-
HFD, 27 AR113Q-NCD, and 24 AR113Q-HFD)
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quadriceps and gastrocnemius by 11 and 7 %, respectively, 
whereas it did not affect the CSA of glycolytic fibers (Sup-
plementary Fig. 20a, b). In CTR mice, the HFD caused 
glucose intolerance and insulin resistance (Supplementary 
Fig. 8b, c), signs of metabolic syndrome that normal mice 
develop upon exposure to HFD [35]. However, the HFD did 
not elicit signs of metabolic syndrome in AR113Q mice. 
The HFD increased fat deposition by 2.9- and 3.9-fold in 
AR113Q and CTR mice, respectively (Fig. 5e). Control 
mice fed the HFD exhibited a progressive increase in body 
weight (P = 0.00001) from 70 days of age compared to 
control mice fed the NCD (Fig. 5f; Supplementary Fig. 21a, 
b). AR113Q mice also showed a significant (P = 0.00001) 
increase in body weight starting from 84 days of age and 
were indistinguishable from control mice fed the NCD. 
The body weight of control and AR113Q mice fed the HFD 
versus NCD was increased by 1.84- and 1.49-fold, respec-
tively, indicating that AR113Q are partially resistant to diet-
induced obesity, despite similar food intake and locomotor 
activity (Supplementary Fig. 21c, d). AR113Q mice showed 
reduced performance on an accelerating rotarod (Supple-
mentary Fig. 21e). The performance of control mice fed 
the HFD was significantly decreased, as expected, whereas 
that of AR113Q mice was restored to normal. The HFD 
also increased the force of gastrocnemius (Supplemen-
tary Fig. 21f). Importantly, the HFD extended the median 
life span of AR113Q mice from 161 days to 322 days 
(χ2LR = 3.955, P = 0.047; Gehan–Breslow: P = 0.046) 
(Fig. 5g). These results show that the HFD attenuates dis-
ease manifestations in knock-in SBMA mice.
Metabolic alterations in glycolytic muscles of SBMA 
patients
We next assessed whether metabolic alterations also 
occur in the muscle of SBMA patients. The number of 
NADH-positive fibers was increased by 1.7-fold in the 
muscle of SBMA patients compared to normal subjects 
(Fig. 6a). The expression of the key glycolytic genes, HkII, 
Pfkfb3, and Gapdh, was significantly decreased in the gly-
colytic muscles of SBMA patients, suggesting that glyco-
lysis is impaired in the muscle of SBMA patients (Fig. 6b). 
Finally, the phosphorylation of the mTOR downstream tar-
get S6K1 was augmented in the muscle of SBMA patients 
compared to control subjects, indicating that mTOR 
signaling is enhanced in SBMA patients (Fig. 6c). These 
results show metabolic alterations in the muscle of SBMA 
patients, thereby supporting the biological relevance of our 
findings in pathogenesis.
Discussion
That primary cell-autonomous degenerative processes 
occur in SBMA muscle is supported by multiple lines of 
evidence [84], including the observations that abnormali-
ties were detected in cultured myotubes isolated from the 
quadriceps of SBMA patients [52], modulation of expres-
sion of non-expanded as well as polyglutamine-expanded 
AR in muscle modifies disease [17, 59, 77], and interven-
tion to reduce the accumulation of polyglutamine-expanded 
AR selectively in muscle is beneficial in SBMA mice [70]. 
What is less obvious is how expression of polyglutamine-
expanded AR causes damage to muscle, and how this 
in turn contributes to the metabolic alterations found in 
SBMA patients [75]. Skeletal muscle plays a central role 
in the regulation of glucose and fatty acid metabolism [25]. 
Skeletal muscle metabolism is dependent on fiber-type 
composition, with slow-twitch oxidative fibers using lipids 
as their main source of energy, and fast-twitch glycolytic 
fibers using glucose. We observed metabolic changes char-
acterized by a glycolytic-to-oxidative switch in muscle in 
Fig. 6  Impaired glycolysis, fiber-type switch, and enhanced mTOR 
signaling in the muscle of SBMA patients. a NADH staining of 
muscle biopsy specimens from SBMA patients and CTR subjects. 
Graph shows mean ± sem, n subjects = 4 SBMA and 6 CTR, n 
fibers = 1964 SBMA and 1924 CTR. b Real-time PCR analysis of 
glycolytic gene transcript levels normalized to beta-glucuronidase 
in the muscle of SBMA patients and CTR subjects. Graph shows 
mean ± sem, n = 5 SBMA and 5 CTR subjects. c Western blotting 
analysis of phosphorylated and total S6K1 in the muscle of SBMA 
patients and CTR subjects. Graph shows mean ± sem, n = 7 CTR 
and 14 SBMA subjects
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both knock-in mice and SBMA patients. In SBMA knock-
in mice, this fiber-type switch preceded atrophy. A similar 
glycolytic-to-oxidative shift in fiber-type composition was 
overt in the quadriceps muscle of transgenic mice ubiqui-
tously expressing polyglutamine-expanded AR, and it was 
attenuated by knockdown of mutant AR solely in muscle 
[45]. A glycolytic-to-oxidative fiber-type switch has also 
been observed in AR knock-out mice, suggesting that poly-
glutamine expansion causes this phenomenon in muscle 
mainly through a loss of function mechanism [50]. Notably, 
in the knock-in SBMA mice the degree of atrophy of glyco-
lytic fibers was higher than that of oxidative fibers. Because 
similar changes in muscle homeostasis occur during aging 
[39], these observations suggest that SBMA muscle may 
undergo premature aging, and that a genetic interaction 
between aging and expression of polyglutamine-expanded 
AR may contribute to SBMA pathogenesis. In addition 
to the loss of function, there is evidence that also gain of 
native AR function contributes to SBMA pathogenesis [63, 
89]. Indeed, overexpression of non-expanded AR solely 
in muscle caused severe muscle atrophy and premature 
death [59], and overexpression of polyglutamine-expanded 
AR in either skeletal muscle or neurons reduced the size 
of fast-glycolytic fibers and induced an oxidative-to-gly-
colytic fiber-type shift in extensor digitorum longus [77]. 
Interestingly, the levels of expression of polyglutamine-
expanded AR correlated with the degree of atrophy, sup-
porting the idea that expression of polyglutamine-expanded 
AR in muscle exerts cell-autonomous, dose-dependent 
toxic effects in muscle. Moreover, our findings suggest that 
dysregulation of androgen signaling in muscle alters mus-
cle and body metabolism, thereby contributing to SBMA 
pathogenesis.
Our lipidomic analysis revealed increased levels of 
lysophosphatidylcholines, lysophosphatidylethanolamines, 
ceramides, diglycerides, and polyunsaturated fatty acids, 
and decreased levels of species enriched in polyunsaturated 
lipids and phosphatidylglycerol. By microarray analysis, 
we observed augmented expression of genes involved in 
lipid biosynthesis and lipolysis. Consistent with the obser-
vation that glycolytic muscles undergo a shift towards 
oxidative metabolism, these findings suggest that lipid 
synthesis and turnover are enhanced in SBMA glycolytic, 
but not oxidative muscles. Another interesting feature that 
characterizes SBMA muscle is the reduction of expression 
and activity of glycolytic enzymes, which also occurs dur-
ing aging [4]. Notably, changes in expression of glycolytic 
genes preceded those in lipid genes, suggesting that altered 
glycolysis contributes to the shift towards oxidative phos-
phorylation. This finding raises the question of whether pol-
yglutamine expansion in AR directly hampers the expres-
sion of key glycolytic genes, such as HkII and Pfkfb, which 
are direct target of AR [60]. Moreover, the expression of 
the glucose transporter GLUT3 was decreased in the mus-
cle of AR113Q mice. GLUT3 has a higher affinity for glu-
cose and at least a fivefold greater transport capacity than 
other glucose transporter family members, such as GLUT1, 
GLUT2 and GLUT4. The decrease in GLUT3 expression 
is consistent with the glycolytic-to-oxidative fiber-type 
switch detected in SBMA muscle and suggests that glucose 
uptake is defective in SBMA glycolytic muscles. Inter-
estingly, the expression of GAPDH was decreased at late 
stages of disease also in soleus, which does not develop 
atrophy and does not show signs of denervation. It is pos-
sible that polyglutamine expansion in the AR directly alters 
the expression of glycolytic genes, which is detrimental in 
muscles that are mostly composed of glycolytic fibers, such 
as quadriceps and gastrocnemius. This effect also occurs 
to a lower extent in muscles that are mostly composed of 
oxidative fibers, but in this case with limited consequences 
on muscle metabolism. Further investigation is required to 
address whether altered glycolysis underlies or contributes 
to the metabolic shift in glycolytic muscles toward oxida-
tive phosphorylation.
Glycolytic-to-oxidative fiber-type switch has also been 
reported in amyotrophic lateral sclerosis (ALS) [68]. 
Similar to SBMA, glycolytic muscles are more severely 
affected in transgenic mouse models of superoxide dis-
mutase 1 (SOD1)-linked ALS [68, 74] and in ALS patients 
[26], and this is likely due to selective vulnerability of fast-
fatiguable motor neurons [74]. Notably, the phenotype of 
mutant SOD1-expressing mice is different from that of 
SBMA mice. Indeed, while mutant SOD1-expressing mice 
develop paralysis of posterior limbs, SBMA mice do not 
develop paralysis even at late stages of disease, indicating 
that the degenerating motor neurons maintain their ability 
to control muscle contraction to some extent. In SBMA 
muscle, upregulation of denervation markers was detected 
after metabolic changes, indicating that, in contrast to ALS 
mice, in SBMA mice these alterations precede denervation. 
Importantly, the motor neuron number and morphology of 
neuromuscular junctions are preserved in knock-in SBMA 
mice [40], further supporting that the metabolic changes 
detected in SBMA glycolytic muscles are not induced by 
denervation at early stages of disease.
SBMA muscle was characterized by increased rates of 
protein synthesis and degradation in glycolytic muscles. 
Protein synthesis was induced by enhanced activation of 
mTOR signaling, which occurred selectively in atrophic 
muscles, was an early event, and was also observed in the 
muscle of SBMA patients. Dysregulation of mTOR sign-
aling is emerging as a key component of neurodegenera-
tive disease pathogenesis. mTOR signaling is upregulated 
in the muscle of an HD mouse model [95] and in the cor-
tex of mice overexpressing TAR DNA-binding protein 
43 (TDP43) [102]; in contrast, it is downregulated in the 
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muscle of a mouse model of valosin-containing protein-
associated inclusion body myopathy [14], in the striatum of 
HD patients and mice [44], and in the spinal cord of trans-
genic mice expressing mutant SOD1 [109]. mTOR activa-
tion can be elicited in response to denervation and exces-
sive accumulation of amino acids released from increased 
protein breakdown. However, in SBMA muscle mTOR 
activation preceded denervation. It remains to be elucidated 
why mTOR is upregulated in SBMA muscle. We noticed 
that mTOR activation correlated with the physiological 
increase of serum testosterone levels that occurs at approxi-
mately 30 days of age in mice. This observation suggests 
that activation of AR is required for mTOR induction, and 
the crosstalk existing between androgen and mTOR signal-
ing may lead to enhancement of mTOR function and mus-
cle hypertrophy in physiological conditions [5]. In SBMA, 
polyglutamine expansion in the AR may result in aberrant 
and sustained activation of mTOR that in turn can con-
tribute to muscle atrophy during disease progression. Pro-
longed activation of mTORC1 causes a late-onset myopa-
thy characterized by altered autophagy [12]. As a matter of 
fact, autophagy was induced in SBMA muscle and altered 
at very late stages of disease. Although further experimental 
evidence is required to assess the role of mTOR in SBMA 
muscle, it is possible that enhancement of mTOR signaling 
at early stages of disease is compensatory to the increased 
need of protein synthesis and breakdown occurring in 
response to the glycolytic-to-oxidative metabolic switch 
in muscle, but prolonged activation of mTOR may turn to 
be detrimental at later stages of disease. mTOR forms two 
complexes, mTOR complex 1 (mTORC1), which regu-
lates cell metabolism, protein synthesis and autophagy, and 
mTOR complex 2 (mTORC2), which mainly controls cell 
proliferation and survival. In SBMA muscle, mTORC1 is 
activated very early, before induction of denervation, and 
it increases the rate of new protein synthesis. mTORC1 is 
sensitive to rapamycin. Rapamycin exerts beneficial effects 
in several neurodegenerative diseases. In a pharmacologi-
cal model of Parkinson’s disease (PD), rapamycin treat-
ment decreased dopaminergic neuron loss by inhibiting the 
expression of mTORC1-induced pro-apoptotic genes [51], 
and by activating autophagy [22]. Induction of autophagy 
and clearance of aggregates underlie the beneficial effects 
of rapamycin in mouse models of Alzheimer’s disease (AD) 
[10, 98], HD [80], SCA3 [55], and PD [19], and in mice 
overexpressing TDP43 modeling frontotemporal demen-
tia [102]. However, rapamycin worsened the phenotype of 
transgenic mice expressing either mutant SOD1 [109] or 
mutant valosin-containing protein (VCP) [14]. Rapamycin 
treatment resulted in exacerbation of body weight loss in 
SBMA knock-in mice, similar to what has been observed in 
other pathological conditions (reviewed by [53]). It is note-
worthy that prolonged treatment with rapamycin inhibits 
mTORC2 and Akt in myoblast cells [86], and as shown 
here in SBMA muscle. Because Akt-mediated phosphoryl-
ation of polyglutamine-expanded AR promotes degradation 
and reduces toxicity, it is possible that rapamycin-induced 
deterioration of phenotype in SBMA mice results from Akt 
inactivation in muscle [69, 70, 89].
mTOR controls cell metabolism through regulation of 
PGC1α function [20]. PGC1α is upregulated selectively in 
SBMA glycolytic muscles. Different from SBMA, PGC1α 
is downregulated in the muscle of mutant SOD1-linked 
ALS mice [68], and its overexpression selectively in mus-
cle attenuated motor dysfunction, even if it had no effect on 
survival [21]. While in ALS muscle the glycolytic-to-oxi-
dative fiber-type switch is independent of PGC1α [68], our 
results show that in SBMA muscle PGC1α is progressively 
upregulated selectively in atrophic muscles following dis-
ease progression, thereby suggesting a role for this nuclear 
receptor co-regulator in SBMA pathogenesis. Several tran-
scriptional co-regulators that interact with AR and other 
nuclear receptors play an important role in controlling mus-
cle fiber-type composition. For instance, muscle-specific 
ablation of nuclear receptor co-activators, such as Sox6 
and Mediator 1, or co-repressors, such as RIP140, lead to 
a glycolytic-to-oxidative fiber-type switch [13, 47, 76, 93]. 
The upregulation of PGC1α detected in SBMA muscle was 
decreased by treatment of the mice with rapamycin, indi-
cating that PGC1α is induced by mTOR. Muscle-specific 
overexpression of PGC1α leads to a glycolytic-to-oxidative 
fiber-type switch [47], whereas loss of PGC1α function has 
the opposite effect [37]. Moreover, PGC1α controls the 
expression of genes involved in oxidative phosphorylation 
[61]. These observations suggest a model whereby polyglu-
tamine-expanded AR leads to mTOR activation, which in 
turn leads to PGC1α induction and glycolytic-to-oxidative 
fiber-type switch. PGC1α levels and mTOR activation can 
be modulated by a diet enriched with lipids [6, 97]. Impor-
tantly, feeding SBMA mice an HFD decreased mTOR 
signaling activation, reduced the expression of PGC1α as 
well as of genes involved in oxidative phosphorylation, and 
attenuated the glycolytic-to-oxidative metabolic fiber-type 
switch.
PGC1α promotes mitochondrial biogenesis [104]. Con-
sistent with the glycolytic-to-oxidative fiber-type switch 
and the upregulation of PGC1α, genes involved in mito-
chondrial dynamics were induced, and the activity of cit-
rate synthase and the mitochondrial respiratory complexes 
was increased in SBMA muscle. Mitochondrial homeo-
stasis is altered in SBMA [79], and mitochondrial mem-
brane potential was decreased by oligomycin in glycolytic 
SBMA muscles. While the HFD did not affect mitochon-
drial complex activity, it decreased mitochondrial mem-
brane depolarization induced by oligomycin, indicating 
that the HFD improves mitochondrial quality control. 
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Mitochondrial dysfunction is often associated with induc-
tion of autophagy [90]. Autophagy is induced in the muscle 
of SBMA knock-in mice [16, 108], and our results show 
that autophagy flux is altered at late stages of disease. Nota-
bly, TFEB is induced in SBMA muscle, leading to upregu-
lation of expression of several autophagy target genes [16]. 
In neurons, TFEB has been shown to work as a co-factor 
of AR, whose function is diminished by polyglutamine 
expansion [18]. It is possible that in muscle polyglutamine 
expansion in AR leads to a gain of TFEB function, result-
ing in enhanced autophagy. Although TFEB is negatively 
regulated by mTOR [94], we detected concurrent mTOR 
and TFEB activation in SBMA glycolytic, but not oxida-
tive muscles, providing evidence that in disease condi-
tions the two signaling pathways can be simultaneously 
activated. Importantly, the HFD reduced the expression of 
TFEB, linking TFEB to metabolism. Interestingly, an HFD 
attenuated autophagy defects and muscle atrophy caused 
by muscle-specific knock-out of histone deacetylases I and 
II, supporting the idea that HFD rescues autophagy altera-
tions and muscle degeneration [62]. Consistent with this 
observation, the HFD decreased the levels of LC3I while 
increasing the levels of LC3II, suggesting a positive effect 
on autophagosome formation and autophagy flux.
Progressive muscle atrophy and body weight loss are 
prognostic factors for several neurodegenerative dis-
eases, such as AD [54], HD [85], PD [1, 7], and ALS [27]. 
Body weight loss can result from reduced energy intake, 
increased energy expenditure, or both. Weight loss can-
not be explained by decreased food intake in these con-
ditions [85, 101]. Rather, neurodegenerative disorders 
are often associated with a hypermetabolic state [28, 58], 
suggesting that altered energy homeostasis contributes to 
pathogenesis [73]. These systemic metabolic deficits are 
characterized by altered lipid (cholesterol and fatty acid) 
metabolism, as reported in HD [9], and AD [29, 46]. Inter-
estingly, male ALS patients have hypolipidemia [105], 
and decreased levels of low-density lipoprotein have been 
shown to correlate with respiratory impairment [15]. High 
levels of serum cholesterol and triglycerides correlate with 
longer survival, further highlighting the relevance of lipid 
metabolism in ALS [32]. Moreover, epidemiological stud-
ies showed that a higher body fat content is associated 
with a lower risk for ALS [36, 48], whereas a high-carbo-
hydrate/low-fat diet is associated with an increased risk 
for ALS [66]. A beneficial effect of high-calorie diet has 
been proven in patients suffering from HD and ALS [31, 
85, 101, 103], as well as in mice expressing either mutant 
SOD1 [33] or mutant VCP [49]. Notably, an HFD has 
been shown to stabilize body weight loss in ALS patients 
[31]. Recently, in a double-blind, placebo-controlled clini-
cal trial, a high-carbohydrate diet, but not an HFD, ame-
liorated some aspects of disease in ALS patients [103]. 
In this trial, treatment was started after about 20 % body 
weight loss, and it remains to be established whether an 
HFD can be beneficial if treatment is started at earlier 
stages of disease. Different from ALS patients, in SBMA 
patients the average serum lipid levels are on the upper 
range to normal, and low-density lipoprotein levels are 
elevated in some patients [23, 34, 75]. In knock-in SBMA 
mice, we did not detect serum lipid alterations. Feeding 
normal mice an HFD results in development of metabolic 
syndrome characterized by glucose intolerance, insulin 
resistance and obesity [35]. AR113Q mice neither devel-
oped signs of glucose intolerance and insulin resistance 
nor they became obese when fed the HFD. Moreover, the 
HFD increased the weight of fat pad in AR113Q mice to 
a lesser extent compared to control mice. These results 
support the idea that SBMA mice require a higher caloric 
intake compared to control mice. Indeed, skeletal muscle 
represents 30 % of body weight, and a metabolic change 
in muscle towards oxidative phosphorylation is expected 
to impact body metabolism with increased need for fatty 
acids. Therefore, the effect of chronic exposure to HFD 
on metabolism leads to development of metabolic syn-
drome in control mice, but not SBMA mice, in which fatty 
acids are used by glycolytic muscles that have undergone 
a shift towards oxidative metabolism. However, before 
this approach can be translated to clinic, it is important to 
consider that an HFD may have undesired side effects in 
patients with serum hyperlipidemia.
Our results provide proof-of-principle that an HFD ame-
liorates muscle pathology, improves motor function, and 
extends life span of a mouse model of SBMA. The HFD 
ameliorated SBMA mouse phenotype by possibly affecting 
several tissues and metabolic pathways. In addition to mus-
cle, the effect of diet may also come from adipose tissue. AR 
is highly expressed in adipose tissue, and the effect of poly-
glutamine expansion in AR on this peripheral tissue remains 
to be addressed. Our findings suggest an unprecedented role 
for adipose tissue in SBMA. Notably, androgen signaling 
mediated by the AR inhibits adipocyte differentiation and 
promotes lipolysis [65]. Adipose tissue controls whole body 
insulin sensitivity. Interestingly, pan-tissue knock-out of AR 
in mouse results in increased fat pad mass with normal insu-
lin sensitivity and reduced body weight [78]. On the other 
hand, adipose tissue-specific knock-out of AR resulted in 
hyperinsulinemia in the absence of obesity, and when fed an 
HFD, the adipose tissue-specific AR knock-out mice devel-
oped obesity, hyperglycemia, and impaired insulin secre-
tion. Another important aspect concerning adipose tissue 
and metabolism is the interplay between androgens and adi-
pokine signaling [65]. High molecular weight adiponectin is 
expressed in white adipose tissue, increases insulin sensitiv-
ity, and is downregulated in obesity. Androgens inhibit the 
release of high molecular weight adiponectin, and castration 
141Acta Neuropathol (2016) 132:127–144 
1 3
or AR knock-out increased the serum levels of adiponec-
tin. Further analysis will establish whether polyglutamine 
expansion in the AR alters adipokine signaling in SBMA. 
Our findings are consistent with a model whereby poly-
glutamine expansion in AR, in addition to conferring toxic 
gain of functions, leads to loss of AR function in muscle and 
possibly other tissues, such as adipose tissue. Some of these 
aspects were attenuated by the HFD, suggesting that this as 
a novel strategy in support to SBMA patients to modify dis-
ease onset, progression, and outcome.
Acknowledgments We thank Philippe Pierre (Marseille, France) 
for providing us with the anti-puromycin antibody, Monica Morini, 
Riccardo Navone, Tiziana Lucchetta, and Daniela Cantatore (Istituto 
Italiano di Tecnologia), and Viola Galligioni and Sergio Robbiati 
(University of Trento) for help with animals, Bruno Gavassini (Uni-
versity of Padova) for technical assistance, Giovanni Miotto (Univer-
sity of Padova) for comments and discussion on lipidomic analysis, 
Valentina Adami and Tarcisio Fedrizzi (University of Trento) for help 
with microarray data generation and analysis, and the network Tel-
ethon EuroBioBank. This work was supported by Telethon-Italy and 
Provincia Autonoma di Trento (TCP12013 to M.P., and TCR09003, 
TCP04009 to M.S.), Marie-Curie Reintegration Grants (FP7-256448 
to M.P. and FP7-276981 to F.S.), Marie Curie International Outgo-
ing Fellowships (PIOF-GA-2011-300723 to S.P.), Italian Ministry of 
Health (RF-2011-02350097 to G.S. and M.P.), Association Française 
contre les Myopathies (18722 to G.S. and M.P.), Bando Progetti Stra-
tegici di Ateneo-University of Trento (to M.P.), the Muscular Dys-
trophy Association (92333 to M.P.), the National Institutes of Health 
(R01 NS055746 to A.P.L.), and the European Research Council 
(282310-MyoPHAGY to M.S.).
Compliance with ethical standards 
Conflict of interest The authors have no conflict of interest to 
declare.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Abbott RA, Cox M, Markus H, Tomkins A (1992) Diet, body 
size and micronutrient status in Parkinson’s disease. Eur J Clin 
Nutr 46:879–884
 2. Armirotti A, Basit A, Realini N, Caltagirone C, Bossu P, Spal-
letta G, Piomelli D (2014) Sample preparation and orthogonal 
chromatography for broad polarity range plasma metabolomics: 
application to human subjects with neurodegenerative demen-
tia. Anal Biochem 455:48–54. doi:10.1016/j.ab.2014.03.019
 3. Baskin KK, Winders BR, Olson EN (2015) Muscle as a 
“mediator” of systemic metabolism. Cell Metab 21:237–248. 
doi:10.1016/j.cmet.2014.12.021
 4. Bass A, Gutmann E, Hanzlikova V (1975) Biochemical and his-
tochemical changes in energy supply enzyme pattern of muscles 
of the rat during old age. Gerontologia 21:31–45
 5. Basualto-Alarcon C, Jorquera G, Altamirano F, Jaimov-
ich E, Estrada M (2013) Testosterone signals through 
mTOR and androgen receptor to induce muscle hypertro-
phy. Med Sci Sports Exerc 45:1712–1720. doi:10.1249/
MSS.0b013e31828cf5f3
 6. Bertaggia E, Scabia G, Dalise S, Lo Verso F, Santini F, Vitti P, 
Chisari C, Sandri M, Maffei M (2014) Haptoglobin is required 
to prevent oxidative stress and muscle atrophy. PLoS ONE 
9:e100745. doi:10.1371/journal.pone.0100745
 7. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC 
(1995) Weight change and body composition in patients with 
Parkinson’s disease. J Am Diet Assoc 95:979–983. doi:10.1016/
S0002-8223(95)00269-3
 8. Blaauw B, Canato M, Agatea L, Toniolo L, Mammucari C, 
Masiero E, Abraham R, Sandri M, Schiaffino S, Reggiani C 
(2009) Inducible activation of Akt increases skeletal mus-
cle mass and force without satellite cell activation. FASEB J 
23:3896–3905. doi:10.1096/fj.09-131870
 9. Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I (2010) 
Altered cholesterol and fatty acid metabolism in Huntington 
disease. J Clin Lipidol 4:17–23. doi:10.1016/j.jacl.2009.11.003
 10. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S 
(2010) Molecular interplay between mammalian target of rapa-
mycin (mTOR), amyloid-beta, and Tau: effects on cognitive 
impairments. J Biol Chem 285:13107–13120. doi:10.1074/jbc.
M110.100420
 11. Cai H, Cong WN, Ji S, Rothman S, Maudsley S, Martin B 
(2012) Metabolic dysfunction in Alzheimer’s disease and 
related neurodegenerative disorders. Curr Alzheimer Res 9:5–
17. doi:10.2174/156720512799015064
 12. Castets P, Lin S, Rion N, Di Fulvio S, Romanino K, Guridi M, 
Frank S, Tintignac LA, Sinnreich M, Ruegg MA (2013) Sus-
tained activation of mTORC1 in skeletal muscle inhibits con-
stitutive and starvation-induced autophagy and causes a severe, 
late-onset myopathy. Cell Metab 17:731–744. doi:10.1016/j.
cmet.2013.03.015
 13. Chen W, Zhang X, Birsoy K, Roeder RG (2010) A muscle-spe-
cific knockout implicates nuclear receptor coactivator MED1 in 
the regulation of glucose and energy metabolism. Proc Natl Acad 
Sci USA 107:10196–10201. doi:10.1073/pnas.1005626107
 14. Ching JK, Elizabeth SV, Ju JS, Lusk C, Pittman SK, Weihl CC 
(2013) mTOR dysfunction contributes to vacuolar pathology 
and weakness in valosin-containing protein associated inclusion 
body myopathy. Hum Mol Genet 22:1167–1179. doi:10.1093/
hmg/dds524
 15. Chio A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, 
Palmo A, Galletti R, Marinou K, Papetti L et al (2009) Lower 
serum lipid levels are related to respiratory impairment in 
patients with ALS. Neurology 73:1681–1685. doi:10.1212/
WNL.0b013e3181c1df1e
 16. Chua JP, Reddy SL, Merry DE, Adachi H, Katsuno M, Sobue G, 
Robins DM, Lieberman AP (2014) Transcriptional activation of 
TFEB/ZKSCAN3 target genes underlies enhanced autophagy in 
spinobulbar muscular atrophy. Hum Mol Genet 23:1376–1386. 
doi:10.1093/hmg/ddt527
 17. Cortes CJ, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L, Toku-
naga S, Lopez E, Sopher BL, Bennett CF et al (2014) Muscle 
expression of mutant androgen receptor accounts for sys-
temic and motor neuron disease phenotypes in spinal and bul-
bar muscular atrophy. Neuron 82:295–307. doi:10.1016/j.
neuron.2014.03.001
 18. Cortes CJ, Miranda HC, Frankowski H, Batlevi Y, Young JE, 
Le A, Ivanov N, Sopher BL, Carromeu C, Muotri AR et al 
(2014) Polyglutamine-expanded androgen receptor interferes 
with TFEB to elicit autophagy defects in SBMA. Nat Neurosci 
17:1180–1189. doi:10.1038/nn.3787
142 Acta Neuropathol (2016) 132:127–144
1 3
 19. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rock-
enstein E, Hansen L, Adame A, Galasko D, Masliah E (2010) 
Selective molecular alterations in the autophagy pathway 
in patients with Lewy body disease and in models of alpha-
synucleinopathy. PLoS One 5:e9313. doi:10.1371/journal.
pone.0009313
 20. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha 
VK, Puigserver P (2007) mTOR controls mitochondrial oxida-
tive function through a YY1-PGC-1alpha transcriptional com-
plex. Nature 450:736–740 doi:10.1038/nature06322
 21. Da Cruz S, Parone PA, Lopes VS, Lillo C, McAlonis-Downes 
M, Lee SK, Vetto AP, Petrosyan S, Marsala M, Murphy AN 
et al (2012) Elevated PGC-1alpha activity sustains mitochon-
drial biogenesis and muscle function without extending survival 
in a mouse model of inherited ALS. Cell Metab 15:778–786. 
doi:10.1016/j.cmet.2012.03.019
 22. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, 
Boya P, Vila M (2010) Pathogenic lysosomal depletion in Par-
kinson’s disease. J Neurosci 30:12535–12544. doi:10.1523/
JNEUROSCI.1920-10.2010
 23. Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas 
F, LeGuern E, Tardieu S, Chadarevian R, Giral P, Turpin G 
(2002) A comprehensive endocrine description of Kennedy’s 
disease revealing androgen insensitivity linked to CAG repeat 
length. J Clin Endocrinol Metab 87:3893–3901. doi:10.1210/
jcem.87.8.8780
 24. Demontis F, Perrimon N (2010) FOXO/4E-BP signaling in 
Drosophila muscles regulates organism-wide proteostasis dur-
ing aging. Cell 143:813–825. doi:10.1016/j.cell.2010.10.007
 25. Demontis F, Piccirillo R, Goldberg AL, Perrimon N (2013) The 
influence of skeletal muscle on systemic aging and lifespan. 
Aging Cell 12:943–949. doi:10.1111/acel.12126
 26. Dengler R, Konstanzer A, Kuther G, Hesse S, Wolf W, Strup-
pler A (1990) Amyotrophic lateral sclerosis: macro-EMG and 
twitch forces of single motor units. Muscle Nerve 13:545–550. 
doi:10.1002/mus.880130612
 27. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, 
Couratier P (1999) Nutritional status is a prognostic factor for 
survival in ALS patients. Neurology 53:1059–1063
 28. Desport JC, Torny F, Lacoste M, Preux PM, Couratier P 
(2005) Hypermetabolism in ALS: correlations with clinical 
and paraclinical parameters. Neurodegener Dis. 2:202–207. 
Doi:10.1159/000089626
 29. Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer’s dis-
ease: cholesterol and beyond. Nat Rev Neurosci 12:284–296. 
doi:10.1038/nrn3012
 30. Dibble CC, Manning BD (2013) Signal integration by mTORC1 
coordinates nutrient input with biosynthetic output. Nat Cell 
Biol 15:555–564. doi:10.1038/ncb2763
 31. Dorst J, Cypionka J, Ludolph AC (2013) High-caloric food sup-
plements in the treatment of amyotrophic lateral sclerosis: a 
prospective interventional study. Amyotroph Lateral Scler Fron-
totemporal Degener 14:533–536. doi:10.3109/21678421.2013.8
23999
 32. Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, 
Ludolph AC (2011) Patients with elevated triglyceride and 
cholesterol serum levels have a prolonged survival in amyo-
trophic lateral sclerosis. J Neurol 258:613–617. doi:10.1007/
s00415-010-5805-z
 33. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loef-
fler JP (2004) Evidence for defective energy homeostasis in 
amyotrophic lateral sclerosis: benefit of a high-energy diet in a 
transgenic mouse model. Proc Natl Acad Sci USA 101:11159–
11164. doi:10.1073/pnas.0402026101
 34. Fernandez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, 
Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE 
et al (2011) Efficacy and safety of dutasteride in patients with 
spinal and bulbar muscular atrophy: a randomised placebo-
controlled trial. Lancet Neurol 10:140–147. doi:10.1016/
S1474-4422(10)70321-5
 35. Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila 
MB, Mandarim-de-Lacerda CA (2010) A mouse model of meta-
bolic syndrome: insulin resistance, fatty liver and non-alcoholic 
fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat 
diet. J Clin Biochem Nutr 46:212–223. doi:10.3164/jcbn.09-83
 36. Gallo V, Wark PA, Jenab M, Pearce N, Brayne C, Vermeulen R, 
Andersen PM, Hallmans G, Kyrozis A, Vanacore N et al (2013) 
Prediagnostic body fat and risk of death from amyotrophic 
lateral sclerosis: the EPIC cohort. Neurology 80:829–838. 
doi:10.1212/WNL.0b013e3182840689
 37. Handschin C, Chin S, Li P, Liu F, Maratos-Flier E, Lebrasseur 
NK, Yan Z, Spiegelman BM (2007) Skeletal muscle fiber-type 
switching, exercise intolerance, and myopathy in PGC-1alpha 
muscle-specific knock-out animals. J Biol Chem 282:30014–
30021. doi:10.1074/jbc.M704817200
 38. Harding AE, Thomas PK, Baraitser M, Bradbury PG, Morgan-
Hughes JA, Ponsford JR (1982) X-linked recessive bulbospinal 
neuronopathy: a report of ten cases. J Neurol Neurosurg Psy-
chiatry 45:1012–1019
 39. Holloszy JO, Chen M, Cartee GD, Young JC (1991) Skel-
etal muscle atrophy in old rats: differential changes in 
the three fiber types. Mech Ageing Dev 60:199–213. 
doi:10.1016/0047-6374(91)90131-I
 40. Kemp MQ, Poort JL, Baqri RM, Lieberman AP, Breedlove SM, 
Miller KE, Jordan CL (2011) Impaired motoneuronal retro-
grade transport in two models of SBMA implicates two sites of 
androgen action. Hum Mol Genet 20:4475–4490. doi:10.1093/
hmg/ddr380
 41. Kennedy WR, Alter M, Sung JH (1968) Progressive proximal 
spinal and bulbar muscular atrophy of late onset. A sex-linked 
recessive trait. Neurology 18:671–680
 42. Kornberg A (1955) Lactic dehydrogenase of muscle. In: Colo-
wick SP, Kaplan NO (eds) Methods in enzymology. Academic 
Press, City
 43. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fisch-
beck KH (1991) Androgen receptor gene mutations in X-linked 
spinal and bulbar muscular atrophy. Nature 352:77–79. 
doi:10.1038/352077a0
 44. Lee JH, Tecedor L, Chen YH, Monteys AM, Sowada MJ, 
Thompson LM, Davidson BL (2015) Reinstating aberrant 
mTORC1 activity in Huntington’s disease mice improves 
disease phenotypes. Neuron 85:303–315. doi:10.1016/j.
neuron.2014.12.019
 45. Lieberman AP, Yu Z, Murray S, Peralta R, Low A, Guo S, Yu 
XX, Cortes CJ, Bennett CF, Monia BP et al (2014) Peripheral 
androgen receptor gene suppression rescues disease in mouse 
models of spinal and bulbar muscular atrophy. Cell Rep 7:774–
784. doi:10.1016/j.celrep.2014.02.008
 46. Lim WL, Martins IJ, Martins RN (2014) The involvement of 
lipids in Alzheimer’s disease. J Genet Genomics 41:261–274 
doi:10.1016/j.jgg.2014.04.003
 47. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, 
Puigserver P, Isotani E, Olson EN et al (2002) Transcriptional 
co-activator PGC-1 alpha drives the formation of slow-twitch 
muscle fibres. Nature 418:797–801. doi:10.1038/nature00904
 48. Lindauer E, Dupuis L, Muller HP, Neumann H, Ludolph AC, 
Kassubek J (2013) Adipose tissue distribution predicts sur-
vival in amyotrophic lateral sclerosis. PLoS ONE 8:e67783. 
doi:10.1371/journal.pone.0067783
 49. Llewellyn KJ, Nalbandian A, Jung KM, Nguyen C, Avanesian 
A, Mozaffar T, Piomelli D, Kimonis VE (2014) Lipid-enriched 
diet rescues lethality and slows down progression in a murine 
143Acta Neuropathol (2016) 132:127–144 
1 3
model of VCP-associated disease. Hum Mol Genet. 23:1333–
1344. doi:10.1093/hmg/ddt523
 50. MacLean HE, Chiu WS, Notini AJ, Axell AM, Davey RA, 
McManus JF, Ma C, Plant DR, Lynch GS, Zajac JD (2008) 
Impaired skeletal muscle development and function in male, but 
not female, genomic androgen receptor knockout mice. FASEB 
J 22:2676–2689. doi:10.1096/fj.08-105726
 51. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene 
LA (2010) Rapamycin protects against neuron death in in vitro 
and in vivo models of Parkinson’s disease. J Neurosci 30:1166–
1175. doi:10.1523/JNEUROSCI.3944-09.2010
 52. Malena A, Pennuto M, Tezze C, Querin G, D’Ascenzo C, Silani 
V, Cenacchi G, Scaramozza A, Romito S, Morandi L et al 
(2013) Androgen-dependent impairment of myogenesis in spi-
nal and bulbar muscular atrophy. Acta Neuropathol 126:109–
121. doi:10.1007/s00401-013-1122-9
 53. Mannaa M, Kramer S, Boschmann M, Gollasch M (2013) 
mTOR and regulation of energy homeostasis in humans. J Mol 
Med (Berl) 91:1167–1175. doi:10.1007/s00109-013-1057-6
 54. McKhann G, Drachman D, Folstein M, Katzman R, Price D, 
Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: 
report of the NINCDS-ADRDA Work Group under the auspices 
of Department of Health and Human Services Task Force on 
Alzheimer’s Disease. Neurology 34:939–944
 55. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubin-
sztein DC (2010) Autophagy induction reduces mutant ataxin-3 
levels and toxicity in a mouse model of spinocerebellar ataxia 
type 3. Brain 133:93–104. doi:10.1093/brain/awp292
 56. Milan G, Romanello V, Pescatore F, Armani A, Paik JH, Fras-
son L, Seydel A, Zhao J, Abraham R, Goldberg AL et al (2015) 
Regulation of autophagy and the ubiquitin-proteasome system 
by the FoxO transcriptional network during muscle atrophy. Nat 
Commun 6:6670. doi:10.1038/ncomms7670
 57. Mo K, Razak Z, Rao P, Yu Z, Adachi H, Katsuno M, Sobue G, 
Lieberman AP, Westwood JT, Monks DA (2010) Microarray 
analysis of gene expression by skeletal muscle of three mouse 
models of Kennedy disease/spinal bulbar muscular atrophy. 
PLoS One 5:e12922. doi:10.1371/journal.pone.0012922
 58. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin 
L, Le Bouc Y, Gervais C, Carcelain G, Vassault A et al (2007) 
Early energy deficit in Huntington disease: identification of a 
plasma biomarker traceable during disease progression. PLoS 
ONE 2:e647. doi:10.1371/journal.pone.0000647
 59. Monks DA, Johansen JA, Mo K, Rao P, Eagleson B, Yu Z, 
Lieberman AP, Breedlove SM, Jordan CL (2007) Overexpres-
sion of wild-type androgen receptor in muscle recapitulates 
polyglutamine disease. Proc Natl Acad Sci USA 104:18259–
18264. doi:10.1073/pnas.0705501104
 60. Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW, Park SW, 
Kim KS (2011) Androgen stimulates glycolysis for de novo lipid 
synthesis by increasing the activities of hexokinase 2 and 6-phos-
phofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate can-
cer cells. Biochem J 433:225–233. doi:10.1042/BJ20101104
 61. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag 
S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E 
et al (2003) PGC-1alpha-responsive genes involved in oxidative 
phosphorylation are coordinately downregulated in human dia-
betes. Nat Genet 34:267–273. doi:10.1038/ng1180
 62. Moresi V, Carrer M, Grueter CE, Rifki OF, Shelton JM, Rich-
ardson JA, Bassel-Duby R, Olson EN (2012) Histone dea-
cetylases 1 and 2 regulate autophagy flux and skeletal muscle 
homeostasis in mice. Proc Natl Acad Sci USA 109:1649–1654. 
doi:10.1073/pnas.1121159109
 63. Nedelsky NB, Pennuto M, Smith RB, Palazzolo I, Moore J, Nie 
Z, Neale G, Taylor JP (2010) Native functions of the andro-
gen receptor are essential to pathogenesis in a Drosophila 
model of spinobulbar muscular atrophy. Neuron 67:936–952. 
doi:10.1016/j.neuron.2010.08.034
 64. Niederle B, Mayr R (1978) Course of denervation atrophy in 
type I and type II fibres of rat extensor digitorum longus mus-
cle. Anat Embryol (Berl) 153:9–21
 65. O’Reilly MW, House PJ, Tomlinson JW (2014) Understanding 
androgen action in adipose tissue. J Steroid Biochem Mol Biol 
143:277–284. doi:10.1016/j.jsbmb.2014.04.008
 66. Okamoto K, Kihira T, Kondo T, Kobashi G, Washio M, 
Sasaki S, Yokoyama T, Miyake Y, Sakamoto N, Inaba Yet 
al (2007) Nutritional status and risk of amyotrophic lat-
eral sclerosis in Japan. Amyotroph Lateral Scler 8:300–304. 
doi:10.1080/17482960701472249
 67. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disor-
ders. Annu Rev Neurosci 30:575–621. doi:10.1146/annurev.
neuro.29.051605.113042
 68. Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch 
S, Henriques A, Boutillier AL, Zoll J, Echaniz-Laguna A, Loef-
fler JP et al (2015) A metabolic switch toward lipid use in gly-
colytic muscle is an early pathologic event in a mouse model of 
amyotrophic lateral sclerosis. EMBO Mol Med. doi:10.15252/
emmm.201404433
 69. Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, 
Fischbeck KH, Howell BW, Pennuto M (2007) Akt blocks 
ligand binding and protects against expanded polyglutamine 
androgen receptor toxicity. Hum Mol Genet 16:1593–1603. 
doi:10.1093/hmg/ddm109
 70. Palazzolo I, Stack C, Kong L, Musaro A, Adachi H, Katsuno 
M, Sobue G, Taylor JP, Sumner CJ, Fischbeck KH et al (2009) 
Overexpression of IGF-1 in muscle attenuates disease in a 
mouse model of spinal and bulbar muscular atrophy. Neuron 
63:316–328. doi:10.1016/j.neuron.2009.07.019
 71. Parodi S, Pennuto M (2011) Neurotoxic effects of androgens 
in spinal and bulbar muscular atrophy. Front Neuroendocrinol 
32:416–425. doi:10.1016/j.yfrne.2011.06.003
 72. Pennuto M, Basso M (2015) In Vitro and In Vivo Modeling 
of Spinal and Bulbar Muscular Atrophy. J Mol Neurosci. 
doi:10.1007/s12031-015-0677-4
 73. Pratley RE, Salbe AD, Ravussin E, Caviness JN (2000) Higher 
sedentary energy expenditure in patients with Huntington’s dis-
ease. Ann Neurol 47:64–70
 74. Pun S, Santos AF, Saxena S, Xu L, Caroni P (2006) Selective 
vulnerability and pruning of phasic motoneuron axons in moto-
neuron disease alleviated by CNTF. Nat Neurosci 9:408–419. 
doi:10.1038/nn1653
 75. Querin G, Bertolin C, Da Re E, Volpe M, Zara G, Pegoraro E, 
Caretta N, Foresta C, Silvano M, Corrado D et al (2015) Non-
neural phenotype of spinal and bulbar muscular atrophy: results 
from a large cohort of Italian patients. J Neurol Neurosurg Psy-
chiatry. doi:10.1136/jnnp-2015-311305
 76. Quiat D, Voelker KA, Pei J, Grishin NV, Grange RW, Bassel-
Duby R, Olson EN (2011) Concerted regulation of myofiber-
specific gene expression and muscle performance by the 
transcriptional repressor Sox6. Proc Natl Acad Sci U S A 
108:10196–10201. doi:10.1073/pnas.1107413108
 77. Ramzan F, McPhail M, Rao P, Mo K, Halievski K, Swift-Gallant 
A, Mendoza-Viveros L, Cheng HY, Monks DA (2015) Distinct 
etiological roles for myocytes and motor neurons in a mouse 
model of Kennedy’s disease/spinobulbar muscular atrophy. J Neu-
rosci 35:6444–6451. doi:10.1523/JNEUROSCI.3599-14.2015
 78. Rana K, Davey RA, Zajac JD (2014) Human andro-
gen deficiency: insights gained from androgen recep-
tor knockout mouse models. Asian J Androl 16:169–177. 
doi:10.4103/1008-682X.122590
 79. Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, 
Burnett BG, Fischbeck KH (2009) Mitochondrial abnormalities 
144 Acta Neuropathol (2016) 132:127–144
1 3
in spinal and bulbar muscular atrophy. Hum Mol Genet 18:27–
42. doi:10.1093/hmg/ddn310
 80. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, 
Scaravilli F, Easton DF, Duden R, O’Kane CJ et al (2004) Inhi-
bition of mTOR induces autophagy and reduces toxicity of pol-
yglutamine expansions in fly and mouse models of Huntington 
disease. Nat Genet 36:585–595. doi:10.1038/ng1362
 81. Rocchi A, Pennuto M (2013) New routes to therapy for spi-
nal and bulbar muscular atrophy. J Mol Neurosci 50:514–523. 
doi:10.1007/s12031-013-9978-7
 82. Romanello V, Guadagnin E, Gomes L, Roder I, Sandri C, 
Petersen Y, Milan G, Masiero E, Del Piccolo P, Foretz M 
et al (2010) Mitochondrial fission and remodelling contrib-
utes to muscle atrophy. EMBO J 29:1774–1785. doi:10.1038/
emboj.2010.60
 83. Rusmini P, Polanco MJ, Cristofani R, Cicardi ME, Meroni M, 
Galbiati M, Piccolella M, Messi E, Giorgetti E, Lieberman AP 
et al (2015) Aberrant autophagic response in the muscle of a 
knock-in mouse model of spinal and bulbar muscular atrophy. 
Sci Rep 5:15174. doi:10.1038/srep15174
 84. Sambataro F, Pennuto M (2012) Cell-autonomous and non-cell-
autonomous toxicity in polyglutamine diseases. Prog Neurobiol 
97:152–172. doi:10.1016/j.pneurobio.2011.10.003
 85. Sanberg PR, Fibiger HC, Mark RF (1981) Body weight and 
dietary factors in Huntington’s disease patients compared with 
matched controls. Med J Aust 1:407–409
 86. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley 
AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin 
treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 
22:159–168. doi:10.1016/j.molcel.2006.03.029
 87. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza 
M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Pol-
ishchuk RS et al (2009) A gene network regulating lysosomal 
biogenesis and function. Science 325:473–477. doi:10.1126/
science.1174447
 88. Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo 
E, Stantzou A, Mouisel E, Toniolo L, Ferry A et al (2013) BMP 
signaling controls muscle mass. Nat Genet 45:1309–1318. 
doi:10.1038/ng.2772
 89. Scaramuzzino C, Casci I, Parodi S, Lievens PM, Polanco MJ, 
Milioto C, Chivet M, Monaghan J, Mishra A, Badders N et al 
(2015) Protein arginine methyltransferase 6 enhances poly-
glutamine-expanded androgen receptor function and toxic-
ity in spinal and bulbar muscular atrophy. Neuron 85:88–100. 
doi:10.1016/j.neuron.2014.12.031
 90. Scherz-Shouval R, Elazar Z (2007) ROS, mitochondria and 
the regulation of autophagy. Trends Cell Biol 17:422–427. 
doi:10.1016/j.tcb.2007.07.009
 91. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M (2013) 
Mechanisms regulating skeletal muscle growth and atrophy. 
FEBS J 280:4294–4314. doi:10.1111/febs.12253
 92. Schmidt EK, Clavarino G, Ceppi M, Pierre P (2009) SUnSET, a 
nonradioactive method to monitor protein synthesis. Nat Meth-
ods 6:275–277. doi:10.1038/nmeth.1314
 93. Seth A, Steel JH, Nichol D, Pocock V, Kumaran MK, Fritah A, 
Mobberley M, Ryder TA, Rowlerson A, Scott J et al (2007) The 
transcriptional corepressor RIP140 regulates oxidative metabo-
lism in skeletal muscle. Cell Metab 6:236–245. doi:10.1016/j.
cmet.2007.08.004
 94. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Huynh T, 
Ferron M, Karsenty G, Vellard MC, Facchinetti V et al (2012) A 
lysosome-to-nucleus signalling mechanism senses and regulates 
the lysosome via mTOR and TFEB. EMBO J 31:1095–1108. 
doi:10.1038/emboj.2012.32
 95. She P, Zhang Z, Marchionini D, Diaz WC, Jetton TJ, Kim-
ball SR, Vary TC, Lang CH, Lynch CJ (2011) Molecular 
characterization of skeletal muscle atrophy in the R6/2 mouse 
model of Huntington’s disease. Am J Physiol Endocrinol Metab 
301:E49–E61. doi:10.1152/ajpendo.00630.2010
 96. Soraru G, D’Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani 
L, Gellera C, Moretto G, Pegoraro E, Angelini C (2008) Spinal 
and bulbar muscular atrophy: skeletal muscle pathology in male 
patients and heterozygous females. J Neurol Sci 264:100–105. 
doi:10.1016/j.jns.2007.08.012
 97. Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray 
GA, Smith SR (2005) A high-fat diet coordinately downregu-
lates genes required for mitochondrial oxidative phosphoryla-
tion in skeletal muscle. Diabetes 54:1926–1933. doi:10.2337/
diabetes.54.7.1926
 98. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, 
Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibi-
tion of mTOR by rapamycin abolishes cognitive deficits and 
reduces amyloid-beta levels in a mouse model of Alzheimer’s 
disease. PLoS ONE 5:e9979. doi:10.1371/journal.pone.0009979
 99. Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C 
(2012) Assessment of mitochondrial respiratory chain enzy-
matic activities on tissues and cultured cells. Nat Protoc 
7:1235–1246. doi:10.1038/nprot.2012.058
 100. Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 
89:381–410. doi:10.1152/physrev.00016.2008
 101. Trejo A, Boll MC, Alonso ME, Ochoa A, Velasquez L (2005) 
Use of oral nutritional supplements in patients with Huntington’s 
disease. Nutrition 21:889–894. doi:10.1016/j.nut.2004.12.012
 102. Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, Shen 
CK (2012) Autophagy activators rescue and alleviate pathogen-
esis of a mouse model with proteinopathies of the TAR DNA-
binding protein 43. Proc Natl Acad Sci USA 109:15024–15029. 
doi:10.1073/pnas.1206362109
 103. Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simp-
son EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T et al 
(2014) Hypercaloric enteral nutrition in patients with amyo-
trophic lateral sclerosis: a randomised, double-blind, placebo-
controlled phase 2 trial. Lancet 383:2065–2072. doi:10.1016/
S0140-6736(14)60222-1
 104. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, 
Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC et al (1999) 
Mechanisms controlling mitochondrial biogenesis and respira-
tion through the thermogenic coactivator PGC-1. Cell 98:115–
124. doi:10.1016/S0092-8674(00)80611-X
 105. Yang JW, Kim SM, Kim HJ, Kim JE, Park KS, Kim SH, Lee 
KW, Sung JJ (2013) Hypolipidemia in patients with amyo-
trophic lateral sclerosis: a possible gender difference? J Clin 
Neurol 9:125–129. doi:10.3988/jcn.2013.9.2.125
 106. Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, 
Lieberman AP (2006) Androgen-dependent pathology demon-
strates myopathic contribution to the Kennedy disease pheno-
type in a mouse knock-in model. J Clin Invest 116:2663–2672. 
doi:10.1172/JCI28773
 107. Yu Z, Dadgar N, Albertelli M, Scheller A, Albin RL, Robins 
DM, Lieberman AP (2006) Abnormalities of germ cell matura-
tion and sertoli cell cytoskeleton in androgen receptor 113 CAG 
knock-in mice reveal toxic effects of the mutant protein. Am J 
Pathol 168:195–204. doi:10.2353/ajpath.2006.050619
 108. Yu Z, Wang AM, Adachi H, Katsuno M, Sobue G, Yue Z, Rob-
ins DM, Lieberman AP (2011) Macroautophagy is regulated 
by the UPR-mediator CHOP and accentuates the phenotype of 
SBMA mice. PLoS Genet 7:e1002321. doi:10.1371/journal.
pgen.1002321
 109. Zhang X, Li L, Chen S, Yang D, Wang Y, Wang Z, Le W (2011) 
Rapamycin treatment augments motor neuron degeneration in 
SOD1(G93A) mouse model of amyotrophic lateral sclerosis. 
Autophagy 7:412–425 (pii:14541)
